期刊文献+

前列腺癌患者血清人腺激肽释放酶2水平检测的临床价值 被引量:1

Clinical value of human kallikrein 2 detection on patients with prostate cancer
下载PDF
导出
摘要 目的探讨血清人腺激肽释放酶2(hK2)的检测对于前列腺癌(PCa)患者早期诊断、预后判断和治疗手段的临床价值。方法选取2015年1~12月期间于广州医科大学附属肿瘤医院就诊的25例PCa患者和25例前列腺增生(BPH)患者及25例健康男性作为研究对象,通过酶联免疫吸附试验(ELISA)、放射免疫分析法(RIA)对hK2和前列腺特异性抗原(PSA)水平进行检测。另随机选取进行过根治性前列腺全切术的PCa组患者12例,检测并分析其手术前后hK2水平。该文所得数据采用统计学软件SPSS21.0建模处理。结果PCa组、BPH组和健康组的hK2水平分别为(75.5±24.5)ng/L、(23.3±5.8)ng/L和(22.2±3.56)ng/L,PCa组明显高于BPH组和健康组,差异均具有统计学意义(P<0.05);hK2检测PCa的特异度、准确度分别为89%和78%,25例PCa患者术后的hK2水平[(34.4±10.5)ng/L]与术前[(80.2±24.5)ng/L]相比较显著下降,差异有统计学意义(P<0.05)。结论 hK2诊断PCa患者能有效提高其检测特异度,减少患者不必要的活检率,为患者的早期临床检测、预后判断和治疗提供了新的方向,前景值得进一步挖掘。 Objective To study the clinical value of human kallikrein 2detection on the early diagnosis,prognosis and therapeutic means of patients with prostate cancer.Methods 25 patients with prostate cancer and 25 patients with benign prostatic hyperplasia who were treated in affiliated hospital of Guangzhou Medical University between January 2015 and December 2015 were selected as research objects.Their human kallikrein 2and prostate specific antigen level were detected by ELISA and RIA.25 cases of prostatic cancer after operation of our hospital in synchronization were randomly selected as research objects and their human kallikrein 2level was detected and analysed.All the data was modeling processed by SPSS21.0.Results Human kallikrein 2level of PCa group,BPH group and healthy group was(75.5±24.5)ng/L,(23.3±5.8)ng/L and(22.2±3.56)ng/L respectively,which of PCa group was higher than that of BPH group and healthy group.The difference had statistical significance(P〈0.05).The specific and accuracy of hK2 detecting PCa was 89% and 78%.Compared with before operation[(80.2±24.5)ng/L],hK2 level of 25 patients with prostate cancer[(34.4±10.5)ng/L]significantly decreased and the difference had statistical significance(P〈0.05).Conclusion On diagnosing prostate cancer,human kallikrein 2can improve specific detection,reduce unnecessary detected rate and provide the new direction for early clinical detection,prognosis and therapy.It deserves further promotion.
出处 《国际检验医学杂志》 CAS 2016年第9期1186-1187,共2页 International Journal of Laboratory Medicine
关键词 前列腺癌 人腺激肽释放酶2 前列腺特异性抗原 临床价值 prostate cancer human kallikrein 2 prostate specific antigen clinical value
  • 相关文献

参考文献10

二级参考文献53

  • 1张旭,王少刚,叶章群,李宏召,郑涛,马鑫,黄本荣.腹腔镜前列腺癌根治术治疗早期前列腺癌的临床经验(附10例报告)[J].临床泌尿外科杂志,2004,19(9):516-518. 被引量:35
  • 2陈雅清,屈婉莹,朱明.核素骨显像对诊断前列腺癌骨转移的临床价值[J].中华核医学杂志,1994,14(3):175-175. 被引量:35
  • 3李振雪.BALP在前列腺癌骨转移中的检测意义[J].中国实验诊断学,2006,10(9):1074-1076. 被引量:7
  • 4Darson M F, Pacelli A, Roche Pet al. Human kallikrein 2 expression in prostateadenocarcinoma and lymph node metastases[J]. Urology, 1999; 53(5) :939-944. 被引量:1
  • 5Jansen F H, Roobol M, Jenster G et al. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins [ J ]. Eur Urol, 2009 ; 55 ( 3 ) : 563-574. 被引量:1
  • 6Stephan C, Jung K, Nakamura T et al. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer [J]. Int J Urol, 2006;13(3) :238-243. 被引量:1
  • 7Vaisanen V, Pettersson K, Alanen K et al. Free and total human glandular kallikrein 2 in patients with prostate cancer [J]. Urology, 2006; 68(1): 219-225. 被引量:1
  • 8Becker C, Piironen T, Pettersson K et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum[J]. J Urol, 2000; 163 (1) :311-316. 被引量:1
  • 9沈关心,周汝麟.现代免疫学实验技术[M].北京:人民卫生出版社.2002:158-158. 被引量:1
  • 10Lequin R M. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA) [J]. Clin Chem, 2005; 51 (12): 2415-2416. 被引量:1

共引文献25

同被引文献12

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部